Therapeutics Company Announces U.S. Patent For Heart Therapy Treatment

BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases, has announced a breakthrough in its technological advancements. The United States Patent Office has granted BioCardia Patent No. 11,986,611, titled “Radial and Transendocardial Delivery Catheter.” This patent, which will expire in 2036, represents a considerable milestone in the company's quest to enhance medical methods and systems for delivering therapeutic substances directly to the heart via a minimally invasive radial artery approach. $BioCardia(BCDA.US)$